The initiative will provide practical insights into understanding of obesity pathophysiology and its management.

"Obesity is a complex, chronic condition that requires more than just treatment--it demands continuous medical education, empathy, and coordinated action across the healthcare ecosystem," said Dr.

NEW DELHI: Eli Lilly, the US pharmaceutical giant that gained widespread attention globally with its weight-loss treatments, plans to launch its blockbuster drug - Tirzepatide - in India in 2025 ...

Eli Lilly plans to launch Mounjaro, an anti-diabetes and weight loss drug, in India by 2025. The medication, which is injected weekly, aims to manage obesity and diabetes, although safety concerns ...

U.S. drugmaker Eli Lilly expects to launch Mounjaro, its blockbuster diabetes drug and wildly popular obesity treatment, in India as early as next year after it clears an ongoing regulatory review ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and Mexico in the second half of 2025 as production capacity increases, its ...

U.S. drugmaker Eli Lilly expects to launch Mounjaro, its blockbuster diabetes drug and a wildly popular obesity treatment, in India as early as next year, CEO David Ricks told Reuters on Wednesday.

Feb 28 (Reuters) - Eli Lilly LLY.N expects to launch its obesity drug tirzepatide in India as early as next year, the U.S. drugmaker's CEO David Ricks told Reuters on Wednesday. "We're open to any ...